BIO-TECHNE Corp (TECH) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2022-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2022-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2022-06-30..
Borrowing debt
Overview →Financial period ending 2022-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2022-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2022-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2022-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 12.50M USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | (m) | |
| Commercial paper | (m) | |
| Cash and current securities | 247.03M USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities |
| Total assets | 2.29B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2022-06-30 | (m) | (m) | $12.50M | (m) | (m) | $247.03M | $2.29B | (m) |
| 2022-03-31 | (m) | (m) | $12.50M | (m) | (m) | $231.17M | $2.30B | (m) |
| 2021-12-31 | (m) | (m) | $12.50M | (m) | (m) | $278.98M | $2.30B | (m) |
| 2021-09-30 | (m) | (m) | $12.50M | (m) | (m) | $235.06M | $2.27B | (m) |
| 2021-06-30 | (m) | (m) | $12.50M | (m) | (m) | $231.55M | $2.26B | (m) |
| 2021-03-31 | (m) | (m) | $12.50M | (m) | (m) | $276.24M | $2.08B | (m) |
| 2020-12-31 | (m) | (m) | $12.50M | (m) | (m) | $282.95M | $2.07B | (m) |
| 2020-09-30 | (m) | (m) | $12.50M | (m) | (m) | $287.39M | $2.05B | (m) |
| 2020-06-30 | (m) | (m) | $12.50M | (m) | (m) | $270.89M | $2.03B | (m) |
| 2020-03-31 | (m) | (m) | $12.50M | (m) | (m) | $261.09M | $2.00B | (m) |
| 2019-12-31 | (m) | (m) | $12.50M | (m) | (m) | $243.95M | $2.00B | (m) |
| 2019-09-30 | (m) | (m) | $12.50M | (m) | (m) | $158.41M | $1.93B | (m) |
| 2019-06-30 | (m) | (m) | $12.50M | (m) | (m) | $166.03M | $1.88B | (m) |
| 2019-03-31 | (m) | (m) | $12.50M | (m) | (m) | $178.79M | $1.87B | (m) |
| 2018-09-30 | (m) | (m) | $12.50M | (m) | (m) | $163.72M | $1.87B | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |